VBL Therapeutics to Present at the 29th Annual ROTH Conference

TEL AVIV, Israel, March 07, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics VBLT, a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced it will provide a corporate overview at the 29^th Annual ROTH Conference, being held March 12-15, 2017 at the Ritz Carlton in Dana Point, California.

About VBL 
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company's lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >200 cancer patients and we have observed its efficacy signals in an "all comers" Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 pivotal trial for recurrent Glioblastoma, conducted under an FDA Special Protocol Assessment (SPA).

INVESTOR CONTACT:
Michael Rice
LifeSci Advisors, LLC
(646) 597-6979